Word

AUREGEN BIOTHERAPEUTICS

Status

Pending

Status Code

688

Status Date

Tuesday, February 20, 2024

Serial Number

90609749

Mark Type

4000

Filing Date

Monday, March 29, 2021

Published for Opposition

Tuesday, December 26, 2023

Trademark Owner History

Auregen BioTherapeutics SA - Owner At Publication

Classifications

40 3D printing services for others; Custom 3D printing services; renting of 3D printers; creation of customized three-dimensional shaped parts using rapid prototyping equipment; 3D bioprinting for others; Bioprinting for others; Research in the field of three-dimensional (3D) printing in the nature of bioprinting for others; Technical consultancy in the field of rapid prototype fabrication of new products for others

9 Laboratory apparatus for fabrication of three-dimensional tissues and organs; Biochips for the production of three-dimensional living tissues and organs for research or scientific purposes; bioreactor for cell culturing; bioreactors for laboratory use; bioreactors for research use; cell culture apparatus for laboratory use, namely, cell culture dishes, tissue culture flasks; Nonmedical combination imaging device incorporating a 3D printer for use in research on biomaterials for the creation of prosthetic limbs and grafts; Laboratory apparatus and instruments, namely, apparatus and instruments for thermal imaging, detecting pathogens, performing DNA analysis, incubator, microscope, function generators, oscilloscopes for use in research on biomaterials, also incorporating a 3D printer, for the creation of prosthetic limbs and grafts; print heads for inkjet printers; Scientific research and laboratory apparatus and instruments, namely, apparatus and instruments for thermal imaging, detecting pathogens, performing DNA analysis, incubator, microscope, function generators, oscilloscopes for research on biomaterials, also incorporating a 3D printer, for the creation of prosthetic limbs and grafts in the field of cytology; Laboratory apparatus and instruments, namely, apparatus and instruments for thermal imaging, detecting pathogens, performing DNA analysis, incubator, microscope, function generators, oscilloscopes for research on biomaterials, also incorporating a 3D printer, for the creation of prosthetic limbs and grafts for use in biopharmaceutical discovery and development; Laboratory apparatus and instruments, namely, apparatus and instruments for thermal imaging, detecting pathogens, performing DNA analysis, incubator, microscope, function generators, oscilloscopes for research on biomaterials, also incorporating a 3D printer, for the creation of prosthetic limbs and grafts; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment

7 Three-dimensional (3D) printers; three-dimensional (3D) bioprinters; Machines in the nature of computerized equipment for the generation of three-dimensional shaped parts; machines for manufacturing three dimensional models, namely, computer-aided modeling devices; machines for manufacturing three dimensional (3D) living tissues; machines, namely, three dimensional (3D) bioprinter for the printing of living tissues; cartridges for containing printing material for use with three dimensional printers, sold empty; cartridges for containing bioprinting material for use with three dimensional printers, sold empty; printing cartridges for containing biomaterial for use with three dimensional printers, sold empty; printing cartridges for containing bioink for use with three dimensional printers, sold empty; 3D printers incorporating an imaging device for use in research on biomaterials for the creation of prosthetic limbs and grafts; Combination 3D printers incorporating laboratory apparatus for use in research on biomaterials for the creation of prosthetic limbs and grafts; Combination 3D printers incorporating a scientific research and laboratory apparatus and instruments for research on biomaterials for the creation of prosthetic limbs and grafts in the field of cytology

5 Pharmaceutical preparations for use in the field of 3D bio-printing of tissues and organs for replacing and/or for supporting the function of missing or damaged body parts; Medical preparations based on cellulous nano-fibrils for use in the 3D bio-printing of tissues and organs for medical use; tissue-regenerative pharmaceutical preparations; Biological bone, skin tissue intended for subsequent implantation for skin and cartilage; biological skin and cartilage tissue intended for subsequent implantation; cells for medical use; human allograft tissue; living cells for medical use; Surgical implants comprised of living tissues for guided tissue regeneration; implants comprising living tissue; Implants comprised of living tissue for use in guided tissue regeneration; skin grafts; surgical implants comprised of living tissues; surgical implants of living tissues grown from stem cells; transdermal patches for use to create skin for prosthetic limbs and for skin grafts; Implants comprised of living tissues for transplant; antibodies for use to create skin for prosthetic limbs and for skin grafts; stem cells for medical purposes; engineered biological tissues and organs, namely, human and animal cardiovascular, pulmonary, digestive, hepatobiliary, urological, renal, endocrine, connective, epithelial, muscular, and nervous tissue and organs, for medical purposes; biological molecules to assist in the development of tissue for medical purposes; hemostatic gel matrix preparations for treating wounds; natural biomaterials for augmentation of bone, blood and tissue for medical purposes; processed human donor skin for the replacement of soft tissue; pharmaceutical products for tissue regeneration, for tissue repair, for tissue treatment, whether relating to human or animal tissue; pharmaceutical preparations for the treatment of bone diseases, for cartilaginous diseases, for vascular diseases, for neuronal degeneration, for degeneration of tendons and ligaments, for retinal degeneration, for renal degeneration, degeneration of soft tissue, for diseases with abnormal cell proliferation; natural biomaterials for bone filling for medical purposes; natural biomaterials for filling cartilage for medical purposes; stem cells for medical use; surgical implants of living tissue; surgical cloths for wound protection; surgical implants grown from stem cells and comprised of living tissue; biological tissue cultures for medical use, all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment; Cartridges containing printing material for use with three dimensional printers, filled with natural biomaterials for augmentation of bone and tissue for medical purposes; Cartridges for use with three dimensional printers filled bioprinting material in the nature of living tissue for medical purposes; printing cartridges for use with three dimensional printers, containing bioink in the nature of living tissue for medical purposes

1 Stem cells for research purposes; stem cells for scientific purposes; stem cells for research or scientific purposes; stem cells other than for medical or veterinary purposes; hydrogel polymer edible coatings for tablets; Lactic acid polymers for use in the manufacture of capsules for pharmaceuticals; Aqueous linear polymer gels for use in the manufacture of capsules for pharmaceuticals; Chemical preparations in the nature of photo curable resin compositions comprising polymers for scientific purposes; chemicals for use in polymerisations; engineered biological tissues and tissue arrays, namely, human and animal organ, connective, epithelial, muscular, and nervous tissues and tissue arrays, for use in scientific and medical research; biologically compatible materials, namely, hydrogels used to create polymeric networks used in the manufacture of living tissue for research and scientific purposes; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment

44 Medical services, namely, in the field of gene and cellular immunotherapies and transplantation; Medical diagnostic monitoring and reporting of testing services; human cell and tissue banking services; collection and preservation of human blood and cells for medical use; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment (44(e) basis); medical treatment services; consulting services in the fields of medical treatment and medicines; medical services, namely, plastic surgery and microsurgery, in particular reshaping noses (rhinoplasty) for either cosmetic or reconstructive purposes (1(b) basis)

10 Dental apparatus and instruments, including imaging devices, for medical purposes, for use in dental surgery; surgical synthetic modified implants and transplants with endogenous material, tissue cells or molecules made of synthetic materials for replacement and/or for supporting the function of missing or damaged body parts, not for cardiac disease treatment; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment; all of the above for synthetic implants

42 Technical research in the fields of biomimetics, biomaterials, material adaptation, 3D bioprinting and tissue engineering; research and development of medical devices; research in the field of nanotechnology and nanomaterials; synthetic biology research; robotics research; bioengineering research; nanotherapeutics research; Biological research in the field of three-dimensional (3D) bioprinting; tissue engineering research; research and development of 3D technology and processes; development of rapid prototyping equipment; scientific research consulting in the fields of three-dimensional printing; scientific services relating to the isolation and cultivation of human tissues and cells; scientific and medical research and development in the field of bio-printing; scientific and medical research and development in the field of tissue manufacturing; Tissue engineering in the nature of development and culture of artificial tissues and cells; Tissue engineering services in the nature of development and culture of artificial tissues and cells for scientific and research purposes; Scientific and medical research and analysis services in the field of tissue engineering research, regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals; Scientific research and material testing services in the fields of regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals; research and development of new products for others in the fields of regenerative biotherapies, genomics, biotechnology, chemicals and pharmaceuticals; Autologous and allogeneic tissue engineering in the nature of development and culture of artificial tissues and cells for scientific and research purposes; all the aforementioned for in vivo use in the fields of therapeutic and/or aesthetic treatment

"BIOTHERAPEUTICS"

Trademark Events

Feb 20, 2024

Teas Delete 1(B) Basis Received

Feb 20, 2024

Noa E-Mailed - Sou Required From Applicant

Dec 26, 2023

Official Gazette Publication Confirmation E-Mailed

Dec 26, 2023

Published For Opposition

Dec 6, 2023

Notification Of Notice Of Publication E-Mailed

Nov 20, 2023

Exparte Appeal Terminated

Nov 20, 2023

Approved For Pub - Principal Register

Oct 18, 2023

Teas/Email Correspondence Entered

Oct 18, 2023

Correspondence Received In Law Office

Oct 18, 2023

Teas Request For Reconsideration Received

Oct 18, 2023

Ex Parte Appeal-Instituted

Oct 18, 2023

Jurisdiction Restored To Examining Attorney

Oct 18, 2023

Exparte Appeal Received At Ttab

Jul 19, 2023

Notification Of Subsequent Final Emailed

Jul 19, 2023

Subsequent Final Emailed

Jul 19, 2023

Subsequent Final Refusal Written

Jun 12, 2023

Assigned To Examiner

Apr 3, 2023

Applicant/Correspondence Changes (Non-Responsive) Entered

Apr 1, 2023

Assigned To Lie

Mar 24, 2023

Teas Voluntary Amendment Received

Mar 13, 2023

Teas/Email Correspondence Entered

Mar 13, 2023

Correspondence Received In Law Office

Mar 13, 2023

Teas Response To Office Action Received

Sep 13, 2022

Notification Of Non-Final Action E-Mailed

Sep 13, 2022

Non-Final Action E-Mailed

Sep 13, 2022

Non-Final Action Written

Jul 7, 2022

Notification Of Final Refusal Emailed

Jul 7, 2022

Final Refusal E-Mailed

Jul 7, 2022

Final Refusal Written

May 18, 2022

Teas/Email Correspondence Entered

May 18, 2022

Correspondence Received In Law Office

May 16, 2022

Assigned To Lie

May 10, 2022

Teas Response To Office Action Received

Nov 10, 2021

Notification Of Non-Final Action E-Mailed

Nov 10, 2021

Non-Final Action E-Mailed

Nov 10, 2021

Non-Final Action Written

Nov 8, 2021

Assigned To Examiner

Aug 11, 2021

Preliminary/Voluntary Amendment - Entered

Aug 11, 2021

Assigned To Lie

Aug 6, 2021

Teas Voluntary Amendment Received

Jul 4, 2021

New Application Office Supplied Data Entered

Apr 1, 2021

New Application Entered